Compassionate Use of Remdesivir for Patients with Severe Covid-19

A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-06, Vol.382 (24), p.2327-2336
Hauptverfasser:	Grein, Jonathan, Ohmagari, Norio, Shin, Daniel, Diaz, George, Asperges, Erika, Castagna, Antonella, Feldt, Torsten, Green, Gary, Green, Margaret L, Lescure, François-Xavier, Nicastri, Emanuele, Oda, Rentaro, Yo, Kikuo, Quiros-Roldan, Eugenia, Studemeister, Alex, Redinski, John, Ahmed, Seema, Bernett, Jorge, Chelliah, Daniel, Chen, Danny, Chihara, Shingo, Cohen, Stuart H, Cunningham, Jennifer, D’Arminio Monforte, Antonella, Ismail, Saad, Kato, Hideaki, Lapadula, Giuseppe, L’Her, Erwan, Maeno, Toshitaka, Majumder, Sumit, Massari, Marco, Mora-Rillo, Marta, Mutoh, Yoshikazu, Nguyen, Duc, Verweij, Ewa, Zoufaly, Alexander, Osinusi, Anu O, DeZure, Adam, Zhao, Yang, Zhong, Lijie, Chokkalingam, Anand, Elboudwarej, Emon, Telep, Laura, Timbs, Leighann, Henne, Ilana, Sellers, Scott, Cao, Huyen, Tan, Susanna K, Winterbourne, Lucinda, Desai, Polly, Mera, Robertino, Gaggar, Anuj, Myers, Robert P, Brainard, Diana M, Childs, Richard, Flanigan, Timothy
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral drugs Clinical trials Confidence intervals Coronaviruses COVID-19 Creatinine Dosage Ebola virus Hospitalization Infections Mechanical ventilation Nucleotide analogs Original Oxygen Oxygenation Patients Respiratory diseases Ribonucleic acid RNA Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2007016